European Hematology Association

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

Retrieved on: 
Monday, June 12, 2023
Survivor, EBMT, Radiation, SNMMI, European Hematology Association, Survival, OS, Bone marrow, BMT, HSCT, DCR, TCT, Congress, AML, Patient, EHA, CR, EFS, Haematopoietic system, Transplant, NYSE, Pharmaceutical industry, Actinium

NEW YORK, June 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral presentation at the European Hematology Association 2023 Congress (EHA) in Frankfurt, Germany on June 10.

Key Points: 
  • NEW YORK, June 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral presentation at the European Hematology Association 2023 Congress (EHA) in Frankfurt, Germany on June 10.
  • "We are honored to have been accepted for an oral presentation at EHA," said Sandesh Seth, Chairman and Chief Executive Officer.
  • The majority of patients who achieved dCR are long term survivors, in whom OS and EFS was significant.
  • Iomab-B based conditioning was well-tolerated and provided access to HSCT with curative potential in a vulnerable patient population traditionally not considered eligible for HSCT.

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress

Retrieved on: 
Monday, June 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Abstract, Rituximab, PCNSL, European Hematology Association, DLBCL, Glucocorticoid, Platelet, Lymphoma, Sequence, ITP, Trae Waynes, SSE, Clinical research associate, HKEX, Patient, Randomness, EHA, IVIG, GC, Primary central nervous system lymphoma, ORR, Safety, Medical imaging

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.

Key Points: 
  • Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • As of cut-off date on 6 Feb 2023, 33 patients were enrolled.
  • Both 50mg QD and 30mg QD of orelabrutinib were safe in the treatment of patients with ITP.
  • Among the 22 patients with previous response to GC or IVIG, 75.0% at the 50mg arm achieved the primary endpoint.

Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate

Retrieved on: 
Saturday, June 10, 2023
IIT, CD19, SCR, European Hematology Association, CRS, DLBCL, B-cell maturation antigen, NHL, Cancer, SLE, B-cell lymphoma, MRD, Congress, Patient, Graceling, SAN, Autoimmune disease, Cytokine release syndrome, EHA, CR, Phenotype, ORR, BCMA, Safety, April 12, Vaccine, Pharmaceutical industry, Tanning (leather), Medical imaging, RRMM

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, June 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented longer-term follow-up data from a first-in-human study evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate, in patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma (r/r B-NHL) as an oral presentation (abstract #S234) at the European Hematology Association (EHA2023) Congress.

Key Points: 
  • GC012F is manufactured through a novel next-day FasTCAR process and demonstrated a younger phenotype of CAR-T cells and highly effective tumor killing activity in preclinical animal models.
  • In the single-arm, open label investigator-initiated trial (IIT), nine r/r B-NHL patients were enrolled and treated with GC012F, and completed at least three months of follow-up.
  • All patients’ lymphoma samples expressed CD19, and samples from seven out of eight tested patients expressed BCMA.
  • GC012F also continued to show a favorable safety profile:
    Cytokine release syndrome (CRS) was mostly Grade 1 (56%; 5/9).

Aptose Presents Highlights from Clinical Update

Retrieved on: 
Saturday, June 10, 2023
VEN, European Hematology Association, APS, SYK, JAK, TUS, DLT, G1, Acute myeloid leukemia, MDS, US, AML, Patient, SAN, EHA, CR, FLT3, TSX, Infrared spectroscopy correlation table, Gene family, FDA, G3, International Congress on Tuberculosis, Venetoclax, US FDA, Pharmaceutical industry

SAN DIEGO and TORONTO, June 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a clinical update event held today, June 10, 2023, in conjunction with EHA 2023 International Congress of the European Hematology Association in Frankfurt, Germany. The event included an up-to-date review of clinical data for Aptose’s two investigational products under development for hematologic malignancies: tuspetinib, an oral, myeloid kinase inhibitor in the Phase 1/2 APTIVATE trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. The webcast of the presentation is available on Aptose’s website here.

Key Points: 
  • The webcast of the presentation is available on Aptose’s website here .
  • Aptose provided updated clinical findings with tuspetinib, a potent suppressor of FLT3, SYK, JAK 1/2, mutant forms of cKIT, and the RSK1/2 kinases operative in AML:
    Completed tuspetinib dose escalation and dose exploration Phase 1/2 trial in 77 R/R AML patients.
  • Tuspetinib is being administered as a monotherapy and as a combination doublet with tuspetinib + venetoclax (TUS/VEN), and enrollment has been brisk.
  • 50mg G3 formulation with continuous dosing achieves roughly equivalent PK profile as 900mg original G1 formulation.

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Retrieved on: 
Saturday, June 10, 2023
Graft-versus-host disease, Royal Melbourne Hospital, CD19, European Hematology Association, CRS, ICML, Lymphoma, NHL, Histology, NK, Toxicity, CAR, Asilomar International Conference on Climate Intervention Technologies, Patient, Mantle cell lymphoma, SAN, The Retreat, EHA, Biology, MCL, Conference, Neurotoxicity, Pharmaceutical industry, Lead

SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).
  • NKX019 is an allogeneic, off-the-shelf NK cell therapy candidate derived from healthy donors and engineered to target CD19.
  • The presentations will ensure that the broader clinical and academic community has the opportunity to assess the NKX019 clinical data in a peer-reviewed format.
  • Nkarta plans to provide an update from the NKX019 program, including data from dose expansion cohorts, in 2023.

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

Retrieved on: 
Saturday, June 10, 2023
Technology, Research, Other Technology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, European Hematology Association, CD16, CD20, Cell proliferation, NK, Cell, Doctor of Philosophy, Euronext Paris, IPH, IPHA, Primate, NCR1, EHA, Mouse, Congress, Therapy, DVM, Natural killer T cell, Tetra, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that updated preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) are presented at the European Hematology Association (EHA) 2023 congress.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that updated preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) are presented at the European Hematology Association (EHA) 2023 congress.
  • A surrogate of IPH6501 mediated a potent anti-tumor activity in vivo in CD20+ tumor models in mice.
  • In addition, in ex vivo assays with R/R B-NHL patient samples, IPH6501 was shown to be more efficient than a T cell engager targeting CD20.
  • By providing proliferation and activation signals targeted to NK cells, the tetra-specific NK Cell Engager based on our ANKET® platform leverages the advantages of harnessing NK cell effector functions against cancer cells.

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
PIM1, Ruxolitinib, ASH, European Hematology Association, Diarrhea, JAK, DLT, Trae tha Truth, Toxicity, MF, TSS, Congress, Fibrosis, MMP9, Spleen, Patient, BID, SVR, EHA, Nausea, Cytokine, Society, Pharmaceutical industry

Initial preliminary data was presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2022 .

Key Points: 
  • Initial preliminary data was presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2022 .
  • Updated results were presented in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress, being held June 8-11, 2023 in Frankfurt, Germany as well as virtually on the Congress platform from June 8-11, 2023.
  • Preliminary data of TP-3654 monotherapy in relapsed/refractory myelofibrosis (MF) patients showed spleen volume reduction (SVR), and total symptom score (TSS) improvement.1 Further, TP-3654 may prompt early cytokine changes that may correlate with symptoms response.
  • "We are encouraged by these preliminary clinical data and are pleased that in dose ranges evaluated to date, TP-3654 has been well-tolerated with no myelosuppressive treatment-related adverse events (TRAEs).

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

Retrieved on: 
Friday, June 9, 2023
Graft-versus-host disease, Euronext Growth, Febrile neutropenia, ASH, CD19, European Hematology Association, ALC, CRS, Infection, Venetoclax, Clinical trial, Skin, Cyclophosphamide, FC, Acute promyelocytic leukemia, HSCT, Șaeș, MRD, CAR, Cytokine release syndrome, Patient, DLI, EHA, Alemtuzumab, Host, CRi, CR, FCA, Infrared spectroscopy correlation table, Society, Blinatumomab, Hematopoietic stem cell transplantation, Safety, Vaccine, Medical device, Medical imaging

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical and translational data on its clinical trial BALLI-01 (evaluating UCART22) at the European Hematology Association (EHA) 2023.

Key Points: 
  • NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical and translational data on its clinical trial BALLI-01 (evaluating UCART22) at the European Hematology Association (EHA) 2023.
  • The data presented support the preliminary safety and efficacy of UCART22 in a heavily pretreated relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) population.
  • UCART22 cell expansion was detected in 9 of 13 patients in the FCA LD arm and associated with clinical activity.
  • Overall, these data support the preliminary safety and efficacy of UCART22 in this heavily pretreated r/r B-ALL population.

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
San Francisco, Tretinoin, University, European Hematology Association, CALC, University of California, San Francisco, Cancer, Juvenile myelomonocytic leukemia, Patient, Drug combination, Cytarabine, EHA, Calcitriol, Poster, Hospital, FLU, Pharmaceutical industry, JMML

FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own.
  • These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
  • Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
  • Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

Retrieved on: 
Friday, June 9, 2023
NT, Red blood cell, Cohort, Bone marrow, Patient, Iron, Male, Nosebleed, Transferrin, Fatigue, Diet, Myocardial infarction, Diarrhea, TI, HTB, Adenine, Research, Injection site reaction, Hematology, Heart, Chronic kidney disease, Solar cycle 1, COVID-19, Hematologic disease, Transfusion-dependent anemia, IWG, Biomarker, Acute myeloid leukemia, Erythropoiesis, Spleen, Anemia, Iron overload, ALK2, Therapy, Haematopoiesis, RBC, Ruxolitinib, European Hematology Association, LTB, Hematocrit, Part, Inflammation, MDS, Chronic obstructive pulmonary disease, EHA, RS, Nausea, Periodic breathing, Mouse, AI, CKD, KROS, Pharmaceutical industry, Dietary supplement, Medical device, Medical imaging, Silviculture, Residential care, Copper, Palladium, MF

In addition, Keros announced preclinical data evaluating activin receptor-like kinase-2 (“ALK2”) inhibition, as well as its combination with RKER-050, as potential treatment options for anemia of inflammation.

Key Points: 
  • In addition, Keros announced preclinical data evaluating activin receptor-like kinase-2 (“ALK2”) inhibition, as well as its combination with RKER-050, as potential treatment options for anemia of inflammation.
  • Of these patients, 37 had completed at least 24 weeks of treatment or discontinued as of the data cut-off date (the “evaluated RP2D patients”).
  • Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these evaluated RP2D patients.
  • By targeting ALK2 inhibition to suppress hepcidin, RKER-216 increased iron availability for erythropoiesis and partially rescued anemia in CKD mice.